Digest Network Come funziona
Network
/
Società
Pa
Non verificato

Parabilis Medicines

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

18 comunicati stampa

Guarda tutti i comunicati
18/05/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
07/05/2026
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
14/04/2026
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Parabilis Medicines Expands Executive Leadership Team
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
11/03/2026
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
05/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
08/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
21/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Fiere
Industria
Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
12/11/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
CORRECTING and REPLACING Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
24/10/2025
Eventi
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0